# Pharmacin

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmacin

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.pharmacin.com
- Total disclosed funding: $15M
- Latest round: Series B (Aug 31, 2021)
- Investors on record: 8

## About

Established in 2016 and based in Shenzhen, China, Pharmacin is a pharmaceutical company that focuses on the R&D, and production of modified new drugs. It has additional offices in the US. Ms. Xu, the company's CEO, has 15 experience in drug discovery and development in international pharmaceutical companies, including Novartis and Boehringer Ingelheim, who focuses on new drug targets for immunology and cardiovascular disease.

It develops modified new drugs for oncology, endocrine, psychiatric, and immunology diseases. The pipe products,HLK-1001 for oncology, and HLK-6002 and HLK-6006 for immunology diseases, have entered into the clinial phase. The company adopts many technologies, such as insoluble drug solubilization technology, slow and controlled release technology, freeze-drying technology, and external preparation technology.

## Funding rounds

- Series B, Aug 31, 2021, $15M — Shenzhen HTI, Huatai Zijin Investment, Dayou Capital
- Series B, Feb 25, 2021 — Kaitai Capital
- Series A, May 31, 2018 — China Reform Tus Fund, Ruihong Investment
- Series A, Apr 14, 2017 — Lotus Lake Capital, Shenzhen Yuankang Investment Management

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- Shenzhen Yuankang Investment Management — Series A
- China Reform Tus Fund (https://capitalatlas.ai/funds/china-reform-tus-fund) — Series A
- Ruihong Investment — Series A
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series B
- Shenzhen HTI (https://capitalatlas.ai/funds/shenzhen-hti) — Series B
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series B
- Dayou Capital (https://capitalatlas.ai/funds/dayou-capital) — Series B